Philips partners for non-drug delirium options; Proteus appoints a CCO;

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific recall of its cardiology guidewire deemed Class 1 by FDA. Article | Follow @VarunSaxena2

@EmilyWFierce: : Discounts not enough to sway U.K. gatekeeper to back Roche's Kadcyla. FiercePharmaMarketing report | Follow @EmilyWFierce

> Philips ($PHG) and the Charité-Universitätsmedizin Berlin have launched a joint research program on ways for non-drug solutions to prevent or reduce the impact of delirium in the critical care environment. More

> Proteus Digital Health has appointed Molly O'Neill as its new CCO. She was the SVP of business development at Tenet Health. The startup also appointed two board members, including a chairman. More

> Australian researchers have developed a prebiotic 'primordial goo' that they expect could be applied to reduce the risk of infection or rejection of medical device implants. More

Biotech News

@FierceBiotech: GC-1 drug shifts bad 'white' fat into good, calorie-burning 'brown' fat in mice. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Don't want to hear about how many drug approvals a Big Pharma has received in the last 5 years. Small $$ drugs don't mean much at all. | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Merck KGaA, Pfizer bag 'breakthrough' status for PD-L1 immunotherapy. More

> Depomed buys a late-stage pain drug and settles its Endo suit in one swipe. Report

> Radius puts off its FDA filing to be 'respectful' of holiday plans. Article

> Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta. Story

Pharma News

@FiercePharma: WHO meeting could change strain selection for flu vaccines. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: Baxalta Singapore plant gets FDA OK to produce Advate. FiercePharmaAsia story | Follow @EricPFierce

> Advera Health: Novartis, GSK asthma meds linked to more side effects than Merck drugs. Report

> U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha. Story

> Cancer, hep C and other specialty meds to drive global drug market to $1.4T by 2020. Article

Biotech Research News

> Generic alcoholism drug used to flush dormant HIV. Report

> UCSD team targeting new stress pathway in Alzheimer's program. More

> CRISPR/Cas9 2.0: Research team offers an upgrade to gene editing tech. Story

> Bone microenvironment offers new approach on prostate cancer. Item

> GC-1 drug shifts bad 'white' fat into good, calorie-burning 'brown' fat in mice. Article

Vaccines News

> Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine. More

> FDA panel to examine 'maternal vaccines' to protect infants. Report

> Researchers tout vaccine's potential to lower cholesterol. Story

> GlaxoSmithKline Ebola vaccine shows safety in PhI. Article

> WHO meeting could change strain selection for flu vaccines. Item

Pharma Marketing News

> Just say no to drugs (advertising): AMA votes to ban DTC ads. More

> AbbVie's Humira repeats, joined by BMS' Opdivo in leading TV spending for October. Report

> Pay attention, pharma marketers: Men are checking out your brand marketing. Article

> Amgen's Repatha gets a thumbs-down from U.K. cost-effectiveness watchdogs. Item

> Discounts not enough to sway U.K. gatekeeper to back Roche's Kadcyla. Story

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.